We retrieved data on the number of doses, date of administration, and trade names of vaccines for each participant from the electronic health records of the Epidemiological Surveillance Emergency Service of Catalonia of the Department of Health. Participants had received the following vaccines: Comirnaty (BNT162b2, mRNA; BioNTech-Pfizer), Spikevax (mRNA-1273; Moderna), and Vaxzevria (ChAdOx1 nCoV-19; AstraZeneca).
We detected a heterologous prime-boost approach in 11 people (Vaxzevria as a first shot followed by Comirnaty). Thus, participants’ vaccine type is categorized according to the type of their first dose.
We used a two-part strategy to identify participants infected with SARS-CoV-2 prior to the 2021 study visit a) positive viral detection test (polymerase chain reaction or antigen test) prior to sample collection in 2021, self-reported in study questionnaires, or identified through record linkage with the SARS-CoV-2 test registry from the Epidemiological Surveillance Emergency Service of Catalonia of the Department of Health,37 and b) seropositivity based on our antibody data using the following criteria: seropositivity in the prevaccination 2020 serology sample, or seropositivity to N-antigen in 2021 sample, given that the available vaccines do not contain or produce N-antigen.
We detected a heterologous prime-boost approach in 11 people (Vaxzevria as a first shot followed by Comirnaty). Thus, participants’ vaccine type is categorized according to the type of their first dose.
We used a two-part strategy to identify participants infected with SARS-CoV-2 prior to the 2021 study visit a) positive viral detection test (polymerase chain reaction or antigen test) prior to sample collection in 2021, self-reported in study questionnaires, or identified through record linkage with the SARS-CoV-2 test registry from the Epidemiological Surveillance Emergency Service of Catalonia of the Department of Health,37 and b) seropositivity based on our antibody data using the following criteria: seropositivity in the prevaccination 2020 serology sample, or seropositivity to N-antigen in 2021 sample, given that the available vaccines do not contain or produce N-antigen.